Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology. The ABCL news feed on Stock Titan aggregates company announcements, clinical updates, financial disclosures, and other material events drawn from AbCellera’s press releases and regulatory filings.
Investors and followers of ABCL can use this page to review news on AbCellera’s internal pipeline, including its lead programs ABCL635 and ABCL575. Recent announcements describe ABCL635 as a potential first-in-class non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause, now in a Phase 1/2 clinical trial, and ABCL575 as an Fc-silenced, half-life extended investigational antibody therapy in a Phase 1 study for moderate-to-severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions.
The ABCL news stream also captures business and corporate developments, such as quarterly business results, updates on partner-initiated programs and molecules in the clinic, and changes in leadership and board composition. In addition, it includes disclosures on legal and intellectual property matters, including AbCellera’s settlement and patent license agreement with Bruker Corporation that resolved patent litigation globally and provides for upfront and royalty payments.
By reviewing this curated news page, readers can follow how AbCellera advances its antibody discovery and development engine, expands its clinical-stage pipeline, and manages its partnered programs and intellectual property. Bookmark this ABCL news section to quickly access company-issued updates, earnings announcements, clinical trial milestones, and other material information relevant to AbCellera’s operations and strategy.
AbCellera (Nasdaq: ABCL) will present at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 7:30 a.m. PT (10:30 a.m. ET). A live audio webcast of the presentation will be available on AbCellera's Investor Relations website, with a replay accessible post-event.
AbCellera specializes in researching and analyzing natural immune systems to discover antibodies for drug development. The company partners with various drug developers to expedite processes and reduce costs in tackling complex drug challenges. More information is available at www.abcellera.com.
AbCellera (Nasdaq: ABCL) reported fiscal year 2022 total revenue of $485 million, up from $375 million in 2021. Net earnings stood at $0.56 per share on a basic basis, consistent with 2021, while diluted earnings rose to $0.50 from $0.48. The company expanded its partnered programs to a cumulative total of 174, initiating 23 new programs in 2022. R&D expenses increased to $107.9 million, reflecting ongoing investments. Key Q4 metrics included a $29.9 million net loss and $21.5 million in revenue. Despite a suspension of U.S. EUA for bebtelovimab, AbCellera aims to enhance its pipeline.
AbCellera (Nasdaq: ABCL) will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time). A live audio webcast of the presentation will be available on AbCellera's Investor Relations website, along with a replay after the event.
AbCellera specializes in finding antibodies through the analysis of natural immune systems, partnering with various drug developers to accelerate drug development while minimizing costs. For further details, visit www.abcellera.com.
AbCellera (NASDAQ: ABCL) will disclose its full year 2022 financial results on February 21, 2023, during a conference call at 2:00 p.m. PT (5:00 p.m. ET). A live audio webcast will be available on AbCellera's Investor Relations website, with a replay following the event. AbCellera is a biotechnology firm that focuses on identifying antibodies through the analysis of natural immune systems, aiding drug developers in creating treatments for various diseases. The company's partnerships span large pharmaceutical firms to small biotechs, enhancing efficiency in drug development.
The United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera (Nasdaq: ABCL), rejecting Berkeley Lights’ challenge to the validity of AbCellera’s U.S. Patent No. 10,087,408.
This patent pertains to microfluidic devices for cell culture and monitoring. Berkeley Lights previously filed multiple petitions with the PTAB, all of which have now been rejected. AbCellera expressed satisfaction with the decision and plans to proceed with its pending patent infringement lawsuit against Berkeley Lights. This outcome reinforces the strength of AbCellera's intellectual property portfolio.
AbCellera (Nasdaq: ABCL) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 2:15 p.m. PT (5:15 p.m. ET). Executives from AbCellera will present, with a live audio webcast available on the company's Investor Relations website. A replay will be accessible after the presentation. AbCellera is a technology company focused on analyzing natural immune systems to discover antibodies for drug development, collaborating with pharmaceutical and biotechnology firms to expedite and enhance their drug development processes.
AbCellera (Nasdaq: ABCL) has initiated a strategic collaboration with AbbVie (NYSE: ABBV) targeting the development of therapeutic antibodies. This multi-year partnership aims to leverage AbCellera's innovative antibody discovery capabilities for up to five targets across various indications. AbCellera will receive research payments, clinical milestones, and royalties from product sales, indicating potential significant revenue streams. CEO Carl Hansen emphasized the collaboration's focus on solving complex antibody discovery challenges to address critical health issues.
Rallybio (Nasdaq: RLYB) and AbCellera (Nasdaq: ABCL) have formed a strategic alliance to develop antibody-based therapeutics for rare diseases. This collaboration combines AbCellera's antibody discovery capabilities with Rallybio's expertise in clinical development. The companies aim to co-develop up to five therapeutic targets, enhancing Rallybio's pipeline and addressing unmet needs in rare metabolic diseases. Both CEOs emphasized the potential for transformative medicines through this partnership.
AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) have announced a strategic alliance aimed at developing novel antibody-based therapeutics for rare diseases. This multi-year collaboration combines AbCellera's advanced antibody discovery capabilities with Rallybio's expertise in rare disease clinical development. The partnership will focus on co-developing up to five therapeutic targets, starting with rare metabolic diseases, addressing significant unmet medical needs. Both companies aim to accelerate drug development and improve patient outcomes.
AbCellera (Nasdaq: ABCL) presented new data on its T-cell engager (TCE) platform at the SITC 37th Annual Meeting, highlighting a diverse panel of CD3-binding antibodies for potential cancer treatments. The research includes proof-of-concept studies demonstrating T-cell engagers that effectively kill cancer cells while minimizing cytokine release. The company aims to enhance the development of bispecific antibodies, addressing the challenges of T-cell activation and specificity. AbCellera's advancements underscore its rapid antibody discovery capabilities and potential market impact.
FAQ
What is the current stock price of Abcellera Biologics (ABCL)?
What is the market cap of Abcellera Biologics (ABCL)?
